Scott D. Collins
Mersana Therapeutics (United States)(US)University of Maine(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Synthesis and Biological Evaluation, interferon and immune responses, Neuroblastoma Research and Treatments
Most-Cited Works
- → High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response(2015)1,424 cited
- → Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers(2013)87 cited
- → Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers(2017)52 cited
- → Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates(2023)47 cited
- → HALOPERIDOL, CLOPENTHIXOL, AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA(1972)41 cited
- → In Vitro Models of the Liver: Disease Modeling, Drug Discovery and Clinical Applications(2019)37 cited
- → Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer(2023)35 cited
- → XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells(2025)25 cited
- → Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines(2020)25 cited
- → Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab(2022)24 cited